Home › Compare › NPPGF vs ABBV
NPPGF yields 11.68% · ABBV yields 3.06%● Live data
📍 NPPGF pulled ahead of the other in Year 1
Combined, NPPGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NPPGF + ABBV for your $10,000?
Nippon Gas Co., Ltd. engages in the supply and sale of LP gas and natural gas in Japan. It operates through LP Gas Business, Electricity Business, and City Gas Business segments. The company supplies LP gas through pipelines to homes built for sale, company dormitories, apartment buildings, other residential apartment complexes, as well as for commercial, industrial, agricultural, and automotive use; and high-pressure gas for commercial and industrial use. It also sells glass-top stoves, built-in stoves, gas oven ranges, gas rice cookers, dishwashers; gas water heaters, instant water heaters, floor heating products, bathroom heater/ventilation/dryer combo systems, and mist saunas; and commercial and industrial gas appliances. In addition, the company sells air-conditioning equipment, including gas and absorption heat pumps, cogeneration systems, and gas infrared heaters; remodeling-related equipment; and household equipment, as well as offers accident insurance agency services. Further, it engages in residential remodeling and consulting business; and the construction of gas, water supply, drainage, and air conditioning/heating equipment. Additionally, the company is involved in the electric power and gas business. Nippon Gas Co., Ltd. was founded in 1955 and is based in Tokyo, Japan.
Full NPPGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.